HDG1901

DRUG2 trials

Sponsors

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Conditions

Type 2 Diabetes

Phase 1

Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

CompletedNCT06634927

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2024-09-22End: 2025-02-12Updated: 2025-08-01

Phase 3

Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes

CompletedNCT06739044

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2023-09-20End: 2025-02-21Updated: 2025-07-28

Related Papers

839-P: Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial

Diabetes2025-06-13